Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Sorrento Therapeutics Inc's Business Segments
Sorrento Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2023
Reportable Segments
2
Largest Segment
Scilex
Total Revenue
$ 15
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2023
- Scilex83.7%
- Sorrento Therapeutics16.3%
Revenue by Reportable Segment - Q2 FY2023
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Scilex | $ 13 | 83.7% |
| Sorrento Therapeutics | $ 2 | 16.3% |
Revenue by Product & Service Category - Q2 FY2023
- Net Product Revenues83.9%
- Scilex Pharmaceuticals Inc. Product Sales83.7%
- Service Revenues16.1%
- Concortis Biosystems Corporation11.8%
- Bioserv Corporation2.6%
- Other Service Revenues1.7%
- Sorrento Therapeutics, Inc. product revenues0.2%
Revenue by Product & Service Category - Q2 FY2023
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Net Product Revenues | $ 13 | 83.9% |
| Scilex Pharmaceuticals Inc. Product Sales | $ 13 | 83.7% |
| Service Revenues | $ 2 | 16.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
4 more categories available
Sign in to unlock the full Sorrento Therapeutics Inc dataset.
Description of Sorrento Therapeutics Inc
Sorrento Therapeutics Inc. is a biopharmaceutical company headquartered in San Diego, California. The company is focused on the development of innovative therapies to treat various types of cancer, autoimmune diseases, and chronic pain.
Sorrento Therapeutics employs a multi-pronged approach to drug development, including the use of proprietary technologies and strategic collaborations. The company's research and development efforts are centered around antibody-based therapies, cell therapy, and gene therapy.
One of the key areas of focus for Sorrento Therapeutics is in the development of antibody-drug conjugates (ADCs). These are targeted therapies that combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs. By selectively delivering powerful drugs directly to cancer cells, ADCs offer the potential for more effective and less toxic treatment options.
Sorrento Therapeutics has also developed a number of antibody-based therapies for the treatment of autoimmune diseases. These therapies work by targeting and neutralizing specific molecules or cells involved in the inflammatory response, thus helping to control the disease progression.
In the field of cell therapy, the company is developing CAR-T cell therapies, which involve genetically engineering a patient's own immune cells to recognize and attack cancer cells. This approach has shown promising results in the treatment of certain types of leukemia and lymphoma.
Another area of focus for Sorrento Therapeutics is gene therapy, which involves the delivery of therapeutic genes into a patient's cells to treat genetic diseases or provide enhanced immune responses against certain diseases. The company is exploring the use of viral vectors and other delivery mechanisms to optimize the delivery of therapeutic genes to specific target cells.
Besides its internal research and development efforts, Sorrento Therapeutics has formed strategic collaborations and partnerships with other pharmaceutical companies to accelerate the development and commercialization of its therapies. These collaborations often involve the licensing of technology or the sharing of resources and expertise.
In addition to its therapeutic programs, Sorrento Therapeutics has also developed a comprehensive portfolio of diagnostic tools that can be used to detect and monitor various diseases. These diagnostics include tests for the detection of certain biomarkers or the presence of specific genes associated with diseases such as cancer.
Overall, Sorrento Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of cancer, autoimmune diseases, and chronic pain. Through its diverse portfolio of antibody-based therapies, cell therapies, gene therapies, and diagnostic tools, the company aims to improve patient outcomes and positively impact the healthcare industry.
Sorrento Therapeutics employs a multi-pronged approach to drug development, including the use of proprietary technologies and strategic collaborations. The company's research and development efforts are centered around antibody-based therapies, cell therapy, and gene therapy.
One of the key areas of focus for Sorrento Therapeutics is in the development of antibody-drug conjugates (ADCs). These are targeted therapies that combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs. By selectively delivering powerful drugs directly to cancer cells, ADCs offer the potential for more effective and less toxic treatment options.
Sorrento Therapeutics has also developed a number of antibody-based therapies for the treatment of autoimmune diseases. These therapies work by targeting and neutralizing specific molecules or cells involved in the inflammatory response, thus helping to control the disease progression.
In the field of cell therapy, the company is developing CAR-T cell therapies, which involve genetically engineering a patient's own immune cells to recognize and attack cancer cells. This approach has shown promising results in the treatment of certain types of leukemia and lymphoma.
Another area of focus for Sorrento Therapeutics is gene therapy, which involves the delivery of therapeutic genes into a patient's cells to treat genetic diseases or provide enhanced immune responses against certain diseases. The company is exploring the use of viral vectors and other delivery mechanisms to optimize the delivery of therapeutic genes to specific target cells.
Besides its internal research and development efforts, Sorrento Therapeutics has formed strategic collaborations and partnerships with other pharmaceutical companies to accelerate the development and commercialization of its therapies. These collaborations often involve the licensing of technology or the sharing of resources and expertise.
In addition to its therapeutic programs, Sorrento Therapeutics has also developed a comprehensive portfolio of diagnostic tools that can be used to detect and monitor various diseases. These diagnostics include tests for the detection of certain biomarkers or the presence of specific genes associated with diseases such as cancer.
Overall, Sorrento Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of cancer, autoimmune diseases, and chronic pain. Through its diverse portfolio of antibody-based therapies, cell therapies, gene therapies, and diagnostic tools, the company aims to improve patient outcomes and positively impact the healthcare industry.
Sorrento Therapeutics Inc. is a biopharmaceutical company committed to the discovery, development, and commercialization of therapies addressing a wide array of diseases. The company operates through several segments, each focusing on distinct therapeutic areas and innovative solutions. Here’s an extensive overview of Sorrento Therapeutics key segments, products, and services:
1. Antibody Development
Sorrento Therapeutics is a leader in the design and production of antibody-based therapies, utilizing its proprietary G-MAB library. This extensive library contains billions of fully human monoclonal antibodies, enabling the precise targeting of various disease indications, including:
- Oncology: Targeting specific tumor antigens to improve treatment efficacy and minimize off-target effects.
- Inflammation: Developing antibodies aimed at modulating the immune response in inflammatory diseases.
- Infectious Diseases: Focusing on antibodies that can neutralize pathogens and provide protective immunity.
Oncology
The oncology segment represents a cornerstone of Sorrentos portfolio, involving a multifaceted approach to cancer treatment:
- Antibody-Drug Conjugates (ADCs): These innovative therapies link cytotoxic drugs to antibodies, allowing for targeted delivery that harms only cancer cells. Sorrento is actively researching ADCs for various cancer types, enhancing the therapeutic index.
- Solid Tumor Programs: Sorrento has dedicated research initiatives targeting different solid tumors, including:
- Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Combination Therapies: Investigating the synergistic potential of combining different therapeutic modalities, including immunotherapy and chemotherapeutics.
Immunotherapy
Sorrento Therapeutics places significant emphasis on immunotherapy to enhance the body’s immune response against cancer:
- CAR-T Cell Therapies: These involve modifying patients T cells to express chimeric antigen receptors (CARs) that specifically recognize and attack tumor cells. Sorrento aims to broaden the applications of CAR-T technologies, extending beyond hematological cancers to solid tumors.
- Research Services: Sorrento offers services in the development and optimization of immunotherapeutic approaches, collaborating with other entities to advance the field.
COVID-19 Solutions
In the wake of the COVID-19 pandemic, Sorrento has rapidly pivoted to develop solutions addressing the crisis:
- Diagnostics: The company is developing rapid point-of-care and lab-based tests to detect SARS-CoV-2, helping facilitate timely diagnosis and treatment.
- Therapeutics: Sorrento is in pursuit of neutralizing antibodies and antiviral agents specifically targeting COVID-19 to help mitigate infection and severity of the disease.
- Vaccines: Engaging in the research and development of vaccine candidates aimed at providing immunity against SARS-CoV-2.
Pain Management
Recognizing the challenges posed by the opioid crisis, Sorrento Therapeutics is dedicated to developing innovative non-opioid pain management solutions:
- Analgesic Products: A range of novel non-opioid analgesics is being developed to manage various pain types, such as:
- Post-operative Pain: Addressing acute pain following surgical procedures.
- Chronic Pain: Strategies for long-term management of persistent pain conditions.
- Neuropathic Pain: Focusing on pain stemming from nerve damage or dysfunction.
- Clinical Development: Conducting clinical trials to establish the safety and efficacy of these innovative products.
Regenerative Medicine
Sorrento is advancing the field of regenerative medicine through the development of products aimed at repairing and regenerating tissues:
- Stem Cell-Based Therapies: Exploring the use of stem cells for various applications, from therapeutic interventions to tissue repair.
- Tissue Engineering: Developing scaffolds and biomaterials that support cell growth and tissue regeneration.
- Cell Therapy Platforms: Engaging in novel approaches to treat conditions such as cardiovascular diseases, orthopedic injuries, and neurological disorders through targeted cell therapies.
Conclusion
In conclusion, Sorrento Therapeutics Inc. offers a comprehensive portfolio of segments, products, and services spanning antibody development, oncology, immunotherapy, COVID-19 solutions, pain management, and regenerative medicine. Their extensive research and development efforts reflect a commitment to delivering innovative treatments that aim to improve the quality of life and clinical outcomes for patients suffering from a variety of diseases.
1. Antibody Development
Sorrento Therapeutics is a leader in the design and production of antibody-based therapies, utilizing its proprietary G-MAB library. This extensive library contains billions of fully human monoclonal antibodies, enabling the precise targeting of various disease indications, including:
- Oncology: Targeting specific tumor antigens to improve treatment efficacy and minimize off-target effects.
- Inflammation: Developing antibodies aimed at modulating the immune response in inflammatory diseases.
- Infectious Diseases: Focusing on antibodies that can neutralize pathogens and provide protective immunity.
Oncology
The oncology segment represents a cornerstone of Sorrentos portfolio, involving a multifaceted approach to cancer treatment:
- Antibody-Drug Conjugates (ADCs): These innovative therapies link cytotoxic drugs to antibodies, allowing for targeted delivery that harms only cancer cells. Sorrento is actively researching ADCs for various cancer types, enhancing the therapeutic index.
- Solid Tumor Programs: Sorrento has dedicated research initiatives targeting different solid tumors, including:
- Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Combination Therapies: Investigating the synergistic potential of combining different therapeutic modalities, including immunotherapy and chemotherapeutics.
Immunotherapy
Sorrento Therapeutics places significant emphasis on immunotherapy to enhance the body’s immune response against cancer:
- CAR-T Cell Therapies: These involve modifying patients T cells to express chimeric antigen receptors (CARs) that specifically recognize and attack tumor cells. Sorrento aims to broaden the applications of CAR-T technologies, extending beyond hematological cancers to solid tumors.
- Research Services: Sorrento offers services in the development and optimization of immunotherapeutic approaches, collaborating with other entities to advance the field.
COVID-19 Solutions
In the wake of the COVID-19 pandemic, Sorrento has rapidly pivoted to develop solutions addressing the crisis:
- Diagnostics: The company is developing rapid point-of-care and lab-based tests to detect SARS-CoV-2, helping facilitate timely diagnosis and treatment.
- Therapeutics: Sorrento is in pursuit of neutralizing antibodies and antiviral agents specifically targeting COVID-19 to help mitigate infection and severity of the disease.
- Vaccines: Engaging in the research and development of vaccine candidates aimed at providing immunity against SARS-CoV-2.
Pain Management
Recognizing the challenges posed by the opioid crisis, Sorrento Therapeutics is dedicated to developing innovative non-opioid pain management solutions:
- Analgesic Products: A range of novel non-opioid analgesics is being developed to manage various pain types, such as:
- Post-operative Pain: Addressing acute pain following surgical procedures.
- Chronic Pain: Strategies for long-term management of persistent pain conditions.
- Neuropathic Pain: Focusing on pain stemming from nerve damage or dysfunction.
- Clinical Development: Conducting clinical trials to establish the safety and efficacy of these innovative products.
Regenerative Medicine
Sorrento is advancing the field of regenerative medicine through the development of products aimed at repairing and regenerating tissues:
- Stem Cell-Based Therapies: Exploring the use of stem cells for various applications, from therapeutic interventions to tissue repair.
- Tissue Engineering: Developing scaffolds and biomaterials that support cell growth and tissue regeneration.
- Cell Therapy Platforms: Engaging in novel approaches to treat conditions such as cardiovascular diseases, orthopedic injuries, and neurological disorders through targeted cell therapies.
Conclusion
In conclusion, Sorrento Therapeutics Inc. offers a comprehensive portfolio of segments, products, and services spanning antibody development, oncology, immunotherapy, COVID-19 solutions, pain management, and regenerative medicine. Their extensive research and development efforts reflect a commitment to delivering innovative treatments that aim to improve the quality of life and clinical outcomes for patients suffering from a variety of diseases.